IBIO-CFB03, an investigational fibrotic therapy, was selected as iBio’s lead candidate for further development, the company announced in…
Articles by José Lopes, PhD
Increasing the production of lipids in the lungs may help slow pulmonary fibrosis progression and potentially lead to new treatment…
A Phase 3 clinical trial in idiopathic pulmonary fibrosis (IPF) patients will be a top clinical development priority for…
An enzyme can start a chain of events that leads to cells involved in tissue scarring reversing their fibrosis-generating activity, British…
Kadmon’s KD025 slowed the progression of idiopathic pulmonary fibrosis and patients’ decline in lung function, a Phase 2 clinical trial…
Swiss researchers have identified a potential blood biomarker for idiopathic pulmonary fibrosis — a precursor to the signaling molecule lysophosphatidic acid. Their…
Actelion Pharmaceuticals’ Tracleer (bosentan) increased the overall survival and reduced the hospitalizations of patients with pulmonary hypertension stemming from idiopathic…
Treatment with Esbriet (pirfenidone)Â reduces cough in patients with idiopathic pulmonary fibrosis (IPF), a new European study finds. The study,…
A gene previously shown to be associated with cancer — called T-cell lymphoma invasion and metastasis 1 (TIAM1) — may…
AÂ Phase 2/3 clinical trial of PBI-4050, a potential new therapy for idiopathic pulmonary fibrosis (IPF), has been approved by the…